Biomea Fusion (BMEA) Competitors $1.61 +0.04 (+2.55%) Closing price 08/4/2025 04:00 PM EasternExtended Trading$1.67 +0.06 (+3.66%) As of 08/4/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BMEA vs. MNPR, VOR, ACB, CRDF, EDIT, ZYBT, DBVT, INZY, IMMP, and DRUGShould you be buying Biomea Fusion stock or one of its competitors? The main competitors of Biomea Fusion include Monopar Therapeutics (MNPR), Vor Biopharma (VOR), Aurora Cannabis (ACB), Cardiff Oncology (CRDF), Editas Medicine (EDIT), Zhengye Biotechnology (ZYBT), DBV Technologies (DBVT), Inozyme Pharma (INZY), Prima BioMed (IMMP), and Bright Minds Biosciences (DRUG). These companies are all part of the "pharmaceutical products" industry. Biomea Fusion vs. Its Competitors Monopar Therapeutics Vor Biopharma Aurora Cannabis Cardiff Oncology Editas Medicine Zhengye Biotechnology DBV Technologies Inozyme Pharma Prima BioMed Bright Minds Biosciences Monopar Therapeutics (NASDAQ:MNPR) and Biomea Fusion (NASDAQ:BMEA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability and earnings. Do analysts recommend MNPR or BMEA? Monopar Therapeutics currently has a consensus price target of $60.00, indicating a potential upside of 43.71%. Biomea Fusion has a consensus price target of $20.10, indicating a potential upside of 1,148.45%. Given Biomea Fusion's stronger consensus rating and higher probable upside, analysts clearly believe Biomea Fusion is more favorable than Monopar Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Monopar Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Biomea Fusion 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 3 Strong Buy rating(s) 3.18 Which has more risk & volatility, MNPR or BMEA? Monopar Therapeutics has a beta of 1.05, indicating that its stock price is 5% more volatile than the S&P 500. Comparatively, Biomea Fusion has a beta of -0.14, indicating that its stock price is 114% less volatile than the S&P 500. Does the media favor MNPR or BMEA? In the previous week, Monopar Therapeutics and Monopar Therapeutics both had 1 articles in the media. Biomea Fusion's average media sentiment score of 1.40 beat Monopar Therapeutics' score of 0.00 indicating that Biomea Fusion is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monopar Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Biomea Fusion 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is MNPR or BMEA more profitable? Monopar Therapeutics' return on equity of -55.39% beat Biomea Fusion's return on equity.Company Net Margins Return on Equity Return on Assets Monopar TherapeuticsN/A -55.39% -51.53% Biomea Fusion N/A -197.71%-134.84% Do insiders & institutionals believe in MNPR or BMEA? 1.8% of Monopar Therapeutics shares are owned by institutional investors. Comparatively, 96.7% of Biomea Fusion shares are owned by institutional investors. 20.5% of Monopar Therapeutics shares are owned by insiders. Comparatively, 18.4% of Biomea Fusion shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has higher valuation & earnings, MNPR or BMEA? Monopar Therapeutics is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMonopar TherapeuticsN/AN/A-$15.59M-$3.48-12.00Biomea FusionN/AN/A-$138.43M-$3.55-0.45 SummaryBiomea Fusion beats Monopar Therapeutics on 7 of the 13 factors compared between the two stocks. Get Biomea Fusion News Delivered to You Automatically Sign up to receive the latest news and ratings for BMEA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BMEA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BMEA vs. The Competition Export to ExcelMetricBiomea FusionMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$58.99M$3.02B$5.51B$9.35BDividend YieldN/A2.46%4.74%4.15%P/E Ratio-0.4518.0629.1424.41Price / SalesN/A272.71435.00101.03Price / CashN/A40.5624.4827.20Price / Book1.138.628.525.77Net Income-$138.43M-$54.98M$3.24B$264.99M7 Day Performance-2.42%-0.87%0.65%-0.68%1 Month Performance-2.66%16.08%7.97%7.08%1 Year Performance-71.60%14.18%30.98%23.80% Biomea Fusion Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BMEABiomea Fusion3.1467 of 5 stars$1.61+2.5%$20.10+1,148.4%-71.8%$58.99MN/A-0.4550Positive NewsUpcoming EarningsMNPRMonopar Therapeutics1.9732 of 5 stars$43.40-3.5%$60.00+38.2%+1,103.2%$275MN/A0.0010Upcoming EarningsVORVor Biopharma0.4752 of 5 stars$2.42+10.0%N/AN/A$274.91MN/A0.00140ACBAurora Cannabis0.3634 of 5 stars$4.78-1.2%N/A-21.7%$272.23M$246.72M80.671,130Upcoming EarningsCRDFCardiff Oncology1.9498 of 5 stars$3.73-6.0%$11.70+213.7%+12.1%$264.11M$680K0.0020Earnings ReportEDITEditas Medicine4.0678 of 5 stars$2.96-6.0%$4.70+58.8%-48.8%$263.70M$32.31M0.00230Upcoming EarningsZYBTZhengye BiotechnologyN/A$5.75+3.6%N/AN/A$261.77M$25.53M0.00278News CoveragePositive NewsAnalyst UpgradeGap DownDBVTDBV Technologies3.1086 of 5 stars$9.86+4.2%$14.75+49.7%+81.6%$258.97M$4.15M0.0080Earnings ReportGap UpINZYInozyme Pharma2.1264 of 5 stars$4.00flat$11.75+193.8%N/A$258.25MN/A-2.3750IMMPPrima BioMed1.4524 of 5 stars$1.80+4.7%$7.00+288.9%-13.0%$251.19M$5.14M0.002,021Positive NewsHigh Trading VolumeDRUGBright Minds Biosciences1.6667 of 5 stars$33.86-4.5%$83.25+145.9%+2,957.8%$249.74MN/A0.00N/AHigh Trading Volume Related Companies and Tools Related Companies MNPR Alternatives VOR Alternatives ACB Alternatives CRDF Alternatives EDIT Alternatives ZYBT Alternatives DBVT Alternatives INZY Alternatives IMMP Alternatives DRUG Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BMEA) was last updated on 8/5/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredLeaked Gov’t Memo Reveals $100 Trillion DeadlineOnly Days Left to Claim Your Share of Trump's $100T Play Trump's economic blueprint is about to go live, an...Stansberry Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biomea Fusion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biomea Fusion With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BMEA Stock Alerts